Booster and Higher Antigen Doses of Inactivated Influenza Vaccine in HIV-Infected Patients

Annals of Pharmacotherapy

Volumn 47, Issue 12, 2013, Pages 1712-1716

  Johnston, Jessica A ^a   Tincher, Lindsey B ^a   Lowe, Denise K ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

booster; high dose; HIV; immunize; increased antigen; influenza; vaccine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INFLUENZA VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA A; INFLUENZA VACCINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROCONVERSION; SEROPREVALENCE;

BOOSTER; HIGH DOSE; HIV; IMMUNIZE; INCREASED ANTIGEN; INFLUENZA; VACCINE;

ANTIGENS, VIRAL; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; VACCINES, INACTIVATED;

EID: 84891668124     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013507901     Document Type: Review

References (20)

1. Centers for Disease Control and Prevention. Seasonal influenza (flu): people at high risk of developing flu-related complications. http://www.cdc.gov/flu/about/disease/high_risk.htm. Accessed July 30, 2013.
2. Radwan HM,Cheeseman SH,Lai KK,Ellison IR.Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season.Clin Infect Dis. 2000;31:604-606.
3. Neuzil KM,Coffet CS,Mitchel EF,Griffen MR.Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection.J Acquir Immune Defic Syndr. 2003;34:304-307.
4. Lin JC,Nichol KL.Excess mortality due to pneumonia or influenza during influenza season among persons with acquired immunodeficiency syndrome.Arch Intern Med. 2001;161:441-446.
5. Centers for Disease Control and Prevention. Seasonal influenza (flu). Summary* recommendations: prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-(ACIP)-United States, 2013-14. http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm. Accessed September 10, 2013.
6. US Food and Drug Administration. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm. Accessed September 10, 2013.
7. Courch RB,Kasel JA.Immunity to influenza in man.Annu Rev Microbiol. 1983;37:529-549.
8. Jefferson T,Di Pietrantonj C,Rivetti Aet al.Vaccines for preventing influenza in healthy adults.Cochrane Database Syst Rev. 2010; (7): CD001269.
9. Tasker SA,Treanor JJ,Paxton WB,Wallace MR.Efficacy of influenza vaccine in HIV-infected persons: a randomized, double-blind, placebo-controlled trial.Ann Intern Med. 1999;131:430-433.
10. Brydak LB,Hryniewicz HJ,Machala M,Horban A.Humoral response to influenza vaccination in HIV-infected patients.Clin Drug Investig. 1999;17:441-449.
11. Nelson KE,Clements ML,Miotti P,Cohn S,Polk BF.The influence of human immunodeficiency virus (HIV) infection on antibody response to influenza vaccines.Ann Intern Med. 1988;109:383-388.
12. Zanetti AR,Amendola A,Besana S,Boschini A,Tanzi E.Safety and immunogenicity of influenza vaccination in individuals infected with HIV.Vaccine. 2002;20:B29-B32.
13. Tebas P,Frank I,Lewis Met al.Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals.AIDS. 2010;24:2187-2192.
14. Kunisaki KM,Janoff EN.Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.Lancet Infect Dis. 2009;9:493-504.
15. Evison J,Farese S,Seitz Met al.Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients.Clin Infect Dis. 2009;48:1402-1412.
16. Miotti PG,Nelson KE,Dallabetta GAet al.The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine.JAMA. 1989;262:779-783.
17. Cooper C,Thorne A,Klein Met al.Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV adults.PLoS One. 2011;6:1-7.
18. El Sahly HM,Davie C,Kotloff Ket al.Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial.J Infect Dis. 2012;205:703-712.
19. McKittrick N,Frank I,Jacobson Jet al.Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons.Ann Intern Med. 2013;158:19-26.
20. Sanofi Pasteur. Sanofi Pasteur's fluzone high-dose vaccine significantly more effective than standard dose fluzone vaccine in preventing influenza in adults 65 years of age and older. http://www.sanofipasteur.com/articles/1254-sanofi-pasteur%E2%80%99s-fluzone-high-dose-vaccine-significantly-more-effective-than-standard-dose-fluzone-vaccine-in-preventing-influenza-in-adults-65-years-of-age-and-older.html. Accessed September 10, 2013.